MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

Home・Aandelen Lijst・Geron Corp

Geron Corp

Gesloten

SectorGezondheidszorg

1.48 4.23

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.42

Max

1.49

Belangrijke statistieken
By Trading Economics
Inkomsten	-10M -29M
Verkoop	788K 48M
Winstmarge	-60.11
Werknemers	258
EBITDA	-14M -24M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+130.5% upside

Dividenden
By Dow Jones
Volgende Winsten	6 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-143M 986M
Vorige openingsprijs	-2.75
Vorige sluitingsprijs	1.48

Nieuwssentiment

By Acuity

38%

62%

133 / 349 Rangschikking in Healthcare

Geron Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 mrt 2026, 23:15 UTC

Belangrijke Nieuwsgebeurtenissen

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30 mrt 2026, 22:36 UTC

Belangrijke Nieuwsgebeurtenissen

Australian Government Rules Out Boots on the Ground in the Middle East

30 mrt 2026, 22:13 UTC

Acquisities, Fusies, Overnames

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30 mrt 2026, 21:00 UTC

Winsten

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30 mrt 2026, 20:15 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30 mrt 2026, 23:40 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

30 mrt 2026, 23:40 UTC

Marktinformatie

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30 mrt 2026, 23:36 UTC

Marktinformatie

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30 mrt 2026, 23:12 UTC

Marktinformatie

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30 mrt 2026, 22:49 UTC

Marktinformatie

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30 mrt 2026, 22:44 UTC

Marktinformatie

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30 mrt 2026, 22:43 UTC

Marktinformatie

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30 mrt 2026, 22:42 UTC

Marktinformatie

South32 Should Go for Growth, Says New Bull -- Market Talk

30 mrt 2026, 22:18 UTC

Marktinformatie

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30 mrt 2026, 22:05 UTC

Marktinformatie

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30 mrt 2026, 21:58 UTC

Acquisities, Fusies, Overnames

Sun Life Financial Agrees to Buy Bell Partners for $350M

30 mrt 2026, 21:39 UTC

Acquisities, Fusies, Overnames

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30 mrt 2026, 21:38 UTC

Acquisities, Fusies, Overnames

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30 mrt 2026, 21:36 UTC

Acquisities, Fusies, Overnames

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30 mrt 2026, 21:25 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

30 mrt 2026, 21:25 UTC

Marktinformatie

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30 mrt 2026, 21:03 UTC

Acquisities, Fusies, Overnames

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30 mrt 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

30 mrt 2026, 20:09 UTC

Winsten

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30 mrt 2026, 20:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Peer Vergelijking

Prijswijziging

Geron Corp Prognose

Koersdoel

By TipRanks

130.5% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3.25 USD 130.5%

Hoogste 5 USD

Laagste 1 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Geron Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Geron Corp - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

133 / 349 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.